- Trial phase
- Phase 1/1b
- Time to market
- At least 4-6 years away, assuming successful completion of Phase 1b, Phase 2, and Phase 3 trials plus regulatory review. The drug is still in very early clinical development.
- Why 2/10
- No hard dated catalyst (PDUFA, pivotal readout, or AdComm) is scheduled for CDX-622 in the next 12 months. The next event would be Phase 1b proof-of-mechanism data in asthma, but no date has been disclosed. CDX-622 is an early-stage pipeline asset that represents a small fraction of Celldex's value; the company's primary value driver is barzolvolimab (Phase 3 for CSU).
CDX-622 has no scheduled binary catalyst in the next 12 months. The next meaningful event would be Phase 1b proof-of-mechanism data in asthma, but no date has been disclosed. For Celldex, the far larger catalyst is the barzolvolimab BLA submission planned for 2027 and any Phase 2 atopic dermatitis data expected in late 2026. CDX-622 is pipeline optionality, not a near-term value driver.
Price Chart
Executive Summary
CDX-622 is an early-stage (Phase 1/1b) bispecific antibody targeting SCF and TSLP, developed by Celldex Therapeutics (CLDX). Positive Phase 1 data presented at EAACI in June 2026 showed rapid, dose-dependent reductions in serum tryptase (mast cell depletion) with a clean safety profile. The drug is advancing into Phase 1b proof-of-concept studies in asthma, allergic rhinitis, and food allergy. However, CDX-622 is a pipeline extension asset for Celldex, whose primary value driver is barzolvolimab (CDX-0159), a Phase 3 anti-KIT antibody for chronic spontaneous urticaria with positive Phase 3 data and a BLA submission planned for 2027. CDX-622 has no hard dated catalyst in the next 12 months, making it a small part of the Celldex thesis.
How It Works
CDX-622 is a bispecific antibody that simultaneously targets two immune-signaling proteins: SCF (stem cell factor) and TSLP (thymic stromal lymphopoietin). By neutralizing SCF, it blocks KIT signaling selectively in mast cells, depleting these allergy-driving immune cells. By also blocking TSLP, it may further dampen allergic inflammation. This dual mechanism is designed to treat mast cell-driven allergic diseases such as asthma, allergic rhinitis, and food allergies.
Trial Status
Phase 1 first-in-human study completed with positive results presented at EAACI June 2026. A Phase 1b proof-of-mechanism study in mild-to-moderate asthma is ongoing. Additional proof-of-concept studies in allergic rhinitis and food allergy are planned.
The Two-Sided Case
Upcoming Catalysts
- Phase 1b proof-of-mechanism data in mild-to-moderate asthma (date not disclosed)
- Initiation of proof-of-concept studies in allergic rhinitis and food allergy (timing not disclosed)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Celldex Therapeutics, Inc. 8-K CLDX ·Originating report